22 мая 2024 г. · Abbvie's top product Humira AbbVie's Humira has increased its revenue from 2011 to 2022, generating 7.9 billion U.S. dollars in 2011 and a ...

17 мар. 2022 г. · AbbVie's drug is the highest-selling pharmaceutical product in history, earning nearly $200 billion since its late 2002 US approval.

12 июл. 2024 г. · Last year, Humira sales fell to $14.4 billion after a record $21.2 billion during the prior year.

25 июл. 2024 г. · In the quarter, the drug brought in net revenue of $2.8 billion, a 29.8% decrease from Q2 2023. Humira saw its steepest decline in the U.S., ...

2 февр. 2024 г. · U.S. Humira net revenues were $2.740 billion , a decrease of 45.3 percent. Internationally, Humira net revenues were $564 million , a decrease ...

29 апр. 2024 г. · Humira net revenues decreased by 35.9% globally, totaling $2.27 billion, and 39.9% in the U.S., totaling $1.771 billion. Internationally, Humira ...

1 мая 2024 г. · Humira revenue plunged more than 30% to $2.3 billion during the first quarter, according to AbbVie. For years, AbbVie has built up a wall of ...

30 окт. 2024 г. · Global Humira net revenues for the quarter were $2.2 billion, a decrease of about 37% year-over-year. William Blair analysts wrote in a ...

U.S. Humira net revenues were $1.771 billion , a decrease of 39.9 percent. Internationally, Humira net revenues were $499 million , a decrease of 15.8 percent ...

3 июн. 2024 г. · The IL-23 inhibitor Skyrizi, first approved in 2019 by the FDA, brought in $7.7 billion in sales last year, itself a jump of 50% on its 2022 ...